Humira lifts AbbVie’s first-quarter results

I feel sorry for Humira legacy reps and all AbbVie Employees.
Miles White saw this scenario playing out way back in 2012 and took appropriate action.
Looks like it was a smart play. Good luck Abbvie employees.
Plans are underway for a massive restructure at Abbvie.


AbbVie Inc

NYSE: ABBV
86.99 USD −2.96 (3.29%)
Jul 20, 11:50 AM EDT

The Humira legacy reps are doomed. There’s a list for RIFs to be implemented around Q419.